SECTION 1. IDENTIFICATION

Product name: Peginterferon Alfa-2b Powder Formulation
Other means of identification: No data available

Manufacturer or supplier's details
Company name of supplier: Merck & Co., Inc
Address: 2000 Galloping Hill Road, Kenilworth, New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Reproductive toxicity: Category 1B

GHS label elements
Hazard pictograms: ⚠️

Signal Word: Danger
Hazard Statements: H360FD May damage fertility. May damage the unborn child.
Precautionary Statements:

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P313 If exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.
Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>&gt;= 80 - &lt;= 100 *</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>No data available</td>
<td>215647-85-1</td>
<td>&gt;= 0.1 - &lt; 1 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage fertility. May damage the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
### SECTION 6. ACCIDENTAL RELEASE MEASURES

- **Personal precautions, protective equipment and emergency procedures**: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- **Environmental precautions**: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

- **Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- **Technical measures**: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding.
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>215647-85-1</td>
<td>TWA (inhalable fraction)</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
- If sufficient ventilation is unavailable, use with local exhaust ventilation.
Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

### Personal protective equipment

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- **Filter type**: Particulates type

**Hand protection**
- **Material**: Chemical-resistant gloves
- **Remarks**: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection**: Wear the following personal protective equipment:
- Safety goggles

**Skin and body protection**: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
- Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance**: powder
- **Color**: White to light yellow
- **Odor**: No data available
- **Odor Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling**: No data available
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Version: 3.6
Revision Date: 08/27/2021
SDS Number: 20512-00020
Date of last issue: 04/09/2021
Date of first issue: 10/09/2014

range

Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Density : 1 g/cm³
Solubility(ies) : No data available
Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity : Not explosive
Viscosity, dynamic : No data available
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Sucrose:
Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

Peginterferon Alfa-2b:
Acute toxicity (other routes of administration): LD50 (Rat): > 20.1 mg/kg
Application Route: Intravenous
LD50 (Monkey): > 9.8 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Peginterferon Alfa-2b:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Peginterferon Alfa-2b:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitization
Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.
Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro
: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Peginterferon Alfa-2b:
Genotoxicity in vitro
: Test Type: reverse mutation assay
Result: negative
  Test Type: Chromosomal aberration
  Test system: Human lymphocytes
  Result: negative

Genotoxicity in vivo
: Test Type: In vivo micronucleus test
  Species: Mouse
  Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Peginterferon Alfa-2b:
Effects on fertility
: Test Type: Fertility/early embryonic development
  Species: Monkey, female
  Application Route: Subcutaneous
  Dose: 0.35 milligram per kilogram
  Symptoms: Effect on estrous cycle

Reproductive toxicity - Assessment
: Clear evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Components:

Peginterferon Alfa-2b:
Target Organs
: Gastrointestinal tract, Immune system, Cardio-vascular system, Endocrine system, Central nervous system, Liver, Respiratory Tract, Eye

Assessment
: Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

**Peginterferon Alfa-2b:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>0.0038 mg/kg</td>
<td>Subcutaneous</td>
<td>9 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>0.0042 mg/kg</td>
<td>Subcutaneous</td>
<td>30 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monkey</td>
<td>0.12 mg/kg</td>
<td>Subcutaneous</td>
<td>30 d</td>
<td>Blood, Bone marrow, Immune system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monkey</td>
<td>0.015 mg/kg</td>
<td>0.077 mg/kg</td>
<td>3 Months</td>
<td>Respiratory Tract, Cardio-vascular system, Central nervous system, Bone marrow</td>
</tr>
</tbody>
</table>

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

**Components:**

**Peginterferon Alfa-2b:**

Inhalation : Symptoms: flu-like symptoms, Gastrointestinal disturbance, mental depression, tingling

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Peginterferon Alfa-2b:**

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available
Persistence and degradability

**Components:**

**Peginterferon Alfa-2b:**

- Biodegradability: Result: Readily biodegradable.
  
  Biodegradation: 63%
  
  Exposure time: 28 d
  
  Method: OECD Test Guideline 301B

Bioaccumulative potential

**Components:**

**Sucrose:**

- Partition coefficient: n-octanol/water: Pow: < 1

**Mobility in soil:**

No data available

**Other adverse effects:**

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods:**

- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
  
  If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation**

**TDG**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations:

- ACGIH: USA. ACGIH Threshold Limit Values (TLV)
- CA BC OEL: Canada. British Columbia OEL
- CA QC OEL: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
- ACGIH / TWA: 8-hour, time-weighted average
- CA AB OEL / TWA: 8-hour Occupational exposure limit
- CA BC OEL / TWA: 8-hour time weighted average
- CA QC OEL / TWAEV: Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Version 3.6
Revision Date: 08/27/2021
SDS Number: 20512-00020
Date of last issue: 04/09/2021
Date of first issue: 10/09/2014

stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 08/27/2021
Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8